Journal
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY
Volume 34, Issue 2, Pages 98-108Publisher
ALLERGY IMMUNOL SOC THAILAND,
DOI: 10.12932/AP0732.34.2.2016
Keywords
atopic dermatitis; skin barrier; skin microbioma; anti-inflammatory therapies; dietary factors; biologics
Categories
Ask authors/readers for more resources
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. It affects infancy, but it is also highly prevalent in adults and it is one of the disease burdens for the patients and their families. Nowadays, AD is recognized as a heterogenous disease with different subtypes with variable clinical manifestations which is affected by the impairments of the skin barrier. The severity of AD dictates the level of treatment. Current AD treatment focuses on restoration of the barrier function, mainly through the use of moisturizers and corticosteroids to control the inflammation, topical calcineurin inhibitors, and immunosuppresive drugs in the most severe cases. However, targeted disease-modifying therapies are under investigation. The most recent findings on the skin microbial dysbiosis is a promising future direction for the development of new treatments. We need to improve the understanding of the complex microbiome-host interactions, the role of autoimmunity, the comparative effectiveness of therapies and the ways to appropriately implement the educational strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available